The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II randomized study of CMB305 and atezolizumab versus atezolizumab in NY-ESO-1+ soft tissue sarcoma: Analysis of immunogenicity, tumor control, and patient survival.
 
Sant P. Chawla
Honoraria - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Consulting or Advisory Role - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Speakers' Bureau - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Research Funding - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
 
Brian Andrew Van Tine
Consulting or Advisory Role - Caris Life Sciences; CytRx Corporation; EMD Serono; Johnson & Johnson; Lilly/ImClone; Novartis; Plexxikon; Threshold Pharmaceuticals
Speakers' Bureau - Caris Life Sciences; Johnson & Johnson; Lilly; Novartis
Research Funding - Merck; Pfizer
Expert Testimony - Me1 Patient
 
Seth Pollack
Consulting or Advisory Role - Amgen; Bayer; Lilly; Nektar; Omeros; PureTech; Tempus
Research Funding - EMD Serono (Inst); Epizyme (Inst); Immune Design (Inst); Janssen Oncology; Karyopharm Therapeutics (Inst); Lilly/ImClone (Inst); Merck (Inst); OncoSec; Presage Biosciences (Inst)
Travel, Accommodations, Expenses - Lilly/ImClone
 
Kristen N. Ganjoo
Consulting or Advisory Role - Daiichi Sankyo; Immune Design; Janssen; Lilly; Novartis
 
Anthony D. Elias
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie; Agilent; Alexion Pharmaceuticals; Align Oncology; Allergan; Amgen; Biogen; Bristol-Myers Squibb; Celgene; Cigna; Gilead Sciences; Illumina; Lilly; Merck; Pfizer; United Health Group
Consulting or Advisory Role - HSIX
Research Funding - Astellas Pharma (Inst); CytRx Corporation (Inst); Eisai (Inst); Eisai (Inst); Genentech (Inst); ImClone Systems (Inst); Incyte (Inst); Johnson & Johnson (Inst); Medivation (Inst)
 
Richard F. Riedel
Employment - Biotech Prosthetic Orthotics of North Carolina (I); Limbguard (I)
Leadership - Biotech Prosthetic Orthotics of North Carolina (I); Limbguard (I)
Stock and Other Ownership Interests - Biotech Prosthetic Orthotics of North Carolina (I); Limbguard (I)
Consulting or Advisory Role - Bayer; Bayer; Daiichi Sankyo; Eisai; GlaxoSmithKline; Ignyta; Lilly; Loxo; Merck; NanoCarrier; Novartis
Research Funding - AADi (Inst); Agios (Inst); Arog (Inst); Astex Pharmaceuticals (Inst); Bayer (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Ignyta (Inst); Immune Design (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); NanoCarrier (Inst); Novartis (Inst); Plexxikon (Inst); Roche/Genentech (Inst); Threshold Pharmaceuticals (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - PandoNet - Limbguard (I)
Travel, Accommodations, Expenses - Daiichi Sankyo; EMD Serono; Ignyta; Janssen; NanoCarrier
 
Steven Attia
Research Funding - AB Science (Inst); Adaptimmune (Inst); Advenchen Laboratories (Inst); Bavarian Nordic (Inst); Bayer (Inst); Blueprint Medicines (Inst); BTG (Inst); CBA Pharma (Inst); CytRx Corporation (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Desmoid Tumor Research Foundation; Epizyme (Inst); Genmab (Inst); Gradalis (Inst); Immune Design (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Philogen (Inst); SpringWorks Therapeutics (Inst); Takeda (Inst); TRACON Pharma (Inst)
Travel, Accommodations, Expenses - Immune Design
 
Edwin Choy
Consulting or Advisory Role - Immune Design
Research Funding - Amgen (Inst); AstraZeneca (Inst); Exelixis (Inst); Immune Design (Inst); Iterion Therapeutics (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Mirati Therapeutics (Inst); Novartis (Inst)
 
Scott H. Okuno
No Relationships to Disclose
 
Mark Agulnik
Consulting or Advisory Role - Bayer; Immune Design; Lilly; Novartis
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Eisai; Janssen
 
Margaret von Mehren
Consulting or Advisory Role - Blueprint Medicines; CytRx Corporation; deciphera; Janssen Oncology
Research Funding - ArQule
Travel, Accommodations, Expenses - Arog
Other Relationship - NCCN
 
Michael B. Livingston
No Relationships to Disclose
 
Vicki Leigh Keedy
Consulting or Advisory Role - Karyopharm Therapeutics
Research Funding - Advenchen Laboratories (Inst); BioMed Valley Discoveries (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Lilly (Inst); medpacto (Inst); Plexxikon (Inst); Roche (Inst); TRACON Pharma (Inst)
 
Claire F. Verschraegen
No Relationships to Disclose
 
Tony Philip
Consulting or Advisory Role - bayer; Foundation medicine; Novartis
Travel, Accommodations, Expenses - bayer; novartis
 
Gerry C. Bohac
Employment - Immune Design
Stock and Other Ownership Interests - Immune Design
 
Sergey Yurasov
Employment - Clovis Oncology; Immune Design
Leadership - Immune Design
Stock and Other Ownership Interests - Clovis Oncology; Immune Design
 
Hailing Lu
Employment - Immune Design
Stock and Other Ownership Interests - Immune Design
 
Michael Chen
Employment - Immune Design
Stock and Other Ownership Interests - Immune Design
 
Robert G. Maki
Honoraria - Lilly; Springer; Wiley
Consulting or Advisory Role - AADi; American Board of Internal Medicine (ABIM); Arcus Ventures; Bayer; Deciphera; Foundation Medicine; Janssen Scientific Affairs; Karyopharm Therapeutics; Lilly/ImClone; SARC: Sarcoma Alliance for Research though Collaboration; TRACON Pharma
Research Funding - Abbvie (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); FORMA Therapeutics (Inst); Immunocore (Inst); Lilly (Inst); Pfizer (Inst); Presage Biosciences (Inst); Regeneron (Inst); TRACON Pharma (Inst); Xencor (Inst)
Patents, Royalties, Other Intellectual Property - Springer and Wiley: Books for contributions I have made to the published texts; Uptodate: I write and edit chapters for their online text book.
Travel, Accommodations, Expenses - Bayer; TRACON Pharma